ARL16 Inhibitors

ARL16 Inhibitors like ML141, NSC23766, and ZCL278 are selective for Cdc42 and Rac1 GTPases, which intersect with cytoskeletal regulation and may share common pathways with ARL16, affecting its overall function. Compounds such as GTPγS can bind to GTPase domains and prevent the hydrolysis of GTP, resulting in a dysfunctional protein locked in an active or inactive state. Brefeldin A and SecinH3 target specific steps in membrane trafficking and GTPase activation, respectively, processes that are crucial for the function of ARL family proteins. CID-1067700 represents a general inhibitor that could have wider effects on the GTPase family, including ARL16.

In addition to these, inhibitors of protein kinases such as Y-27632 can impact the cytoskeletal dynamics and downstream signaling that ARL16 may be involved in. Statins like Lovastatin, Simvastatin, and Mevastatin are known to affect the isoprenylation of GTPases, which is essential for their membrane attachment and subsequent function. By inhibiting the synthesis of isoprenoid intermediates, these compounds can potentially modulate the activity of GTPase family proteins, including ARL16.